Wall Street Zen Upgrades TransMedics Group (NASDAQ:TMDX) to Buy

TransMedics Group (NASDAQ:TMDX) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

TMDX has been the subject of several other research reports. Morgan Stanley raised their price objective on shares of TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research report on Tuesday, December 2nd. Needham & Company LLC raised their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the stock a “buy” rating in a report on Monday, December 8th. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a report on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $144.25.

TransMedics Group Trading Up 1.0%

Shares of TransMedics Group stock opened at $129.84 on Friday. The business has a fifty day simple moving average of $132.32 and a 200-day simple moving average of $125.28. TransMedics Group has a fifty-two week low of $62.07 and a fifty-two week high of $156.00. The firm has a market cap of $4.44 billion, a price-to-earnings ratio of 52.57 and a beta of 2.06. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

Insider Activity

In related news, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer directly owned 15,064 shares of the company’s stock, valued at approximately $2,103,235.68. The trade was a 5.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction that occurred on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the sale, the insider owned 13,955 shares of the company’s stock, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 8,920 shares of company stock worth $1,257,310 over the last quarter. Corporate insiders own 7.00% of the company’s stock.

Institutional Trading of TransMedics Group

Hedge funds and other institutional investors have recently modified their holdings of the company. Whittier Trust Co. of Nevada Inc. grew its stake in TransMedics Group by 981.0% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock valued at $26,000 after purchasing an additional 206 shares in the last quarter. Salomon & Ludwin LLC bought a new position in TransMedics Group during the third quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd acquired a new stake in TransMedics Group in the third quarter valued at approximately $29,000. Optiver Holding B.V. grew its position in TransMedics Group by 248.1% in the third quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after acquiring an additional 191 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in TransMedics Group by 74.3% during the third quarter. Allworth Financial LP now owns 265 shares of the company’s stock valued at $30,000 after buying an additional 113 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.